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ARTICLE OPEN
H7N9 influenza split vaccine with SWE oil-in-water adjuvant
greatly enhances cross-reactive humoral immunity and
protection against severe pneumonia in ferrets
Jørgen de Jonge 1✉, Harry van Dijken1, Femke de Heij1, Sanne Spijkers1,9, Justin Mouthaan1,10, Rineke de Jong2, Paul Roholl3,
Eduardo Alfredo Adami4, Milena Apetito Akamatsu5, Paulo Lee Ho5, Livia Brunner6, Nicolas Collin6, Martin Friede7, José A. Ferreira8 and
Willem Luytjes1
Until universal influenza vaccines become available, pandemic preparedness should include developing classical vaccines against
potential pandemic influenza subtypes. We here show that addition of SWE adjuvant, a squalene-in-water emulsion, to H7N9 split
influenza vaccine clearly enhanced functional antibody responses in ferrets. These were cross-reactive against H7N9 strains from
different lineages and newly emerged H7N9 variants. Both vaccine formulations protected in almost all cases against severe
pneumonia induced by intratracheal infection of ferrets with H7N9 influenza; however, the SWE adjuvant enhanced protection
against virus replication and disease. Correlation analysis and curve fitting showed that both VN- and NI-titers were better
predictors for protection than HI-titers. Moreover, we show that novel algorithms can assist in better interpretation of large data
sets generated in preclinical studies. Cluster analysis showed that the adjuvanted vaccine results in robust immunity and protection,
whereas the response to the non-adjuvanted vaccine is heterogeneous, such that the protection balance may be more easily
tipped toward severe disease. Finally, cluster analysis indicated that the dose-sparing capacity of the adjuvant is at least a factor six,
which greatly increases vaccine availability in a pandemic situation.
npj Vaccines            (2020) 5:38 ; https://doi.org/10.1038/s41541-020-0187-4
INTRODUCTION
Since the first reported human infections with avian H7N9
influenza virus in China in 20131, the virus has been transmitted
from the avian reservoir to humans in a seasonal fashion for
several years, although lately the virus appears quiescent2. The
virus causes a typical influenza-like illness and can progress into a
severe viral pneumonia resulting in an acute respiratory distress
syndrome (ARDS) accompanied with multiorgan failure3,4. Out of
the >1500 laboratory confirmed cases, 39% have succumbed to
the infection5. Epidemiology studies have shown that humans
become infected mainly through exposure to virus-infected
poultry6–9. During the fifth H7N9 infection wave, in 2016/2017,
there was a substantial increase in number of human infections
and the virus covered a larger geographical area2,6. During the
fifth wave, several new strains had evolved to become highly
pathogenic in poultry (HPAI)8,10,11. These isolates had also
acquired a multi-basic cleavage site in HA10,12,13 and mutations
in the PB2 protein12,14, which are associated with a wider tissue
tropism and pathogenicity15,16.
Sustained human-to-human transmission has not been
observed, however, mutational analysis has shown that it takes
three amino-acid changes to acquire human type receptor
specificity17. Studies towards evolution of H7N9 viruses in
humans on strains isolated from human cases show that these
viruses have undergone adaptive evolution and that some sites
have evolved in a parallel fashion in different subjects18. Some
of the amino-acid substitutions are known to contribute to
human adaptation. Together, this indicates that H7N9 viruses
have a pandemic potential, stressing the importance of
preparing for a possible outbreak. The human population is
naive to H7N9 in terms of neutralizing immunity, which allows
the virus to spread more easily once it becomes transmissible
between humans.
The Global Action Plan for influenza vaccines (GAP) of the WHO
recommends several strategies to be better prepared for a
pandemic19,20. One of these strategies is to develop influenza
vaccines against potentially pandemic influenza viruses up to
clinical phase I/II. As a universal influenza vaccine is not yet
available, development of subtype specific vaccines enables rapid
response in the event of a pandemic by that specific subtype.
Careful consideration of which influenza viruses have a potential
to initiate a pandemic is however required and even then, we still
may be surprised by an outbreak of an unexpected subtype. Based
on pandemic potential of H7N9 influenza, this virus was one of the
selected targets for vaccine development. Within the GAP
program, we evaluated an H7N9 split vaccine formulated with
SWE adjuvant, a squalene-in-water emulsion. With the appearance
of new highly pathogenic H7N9 variants and earlier and recent
local outbreaks of other H7Nx subtypes21–23, cross-reactivity of
previously developed vaccines to these variants becomes an
important competence within GAP.
Vaccines prepared from H7N9 viruses are considerably less
immunogenic in terms of generating neutralizing antibodies
than their seasonal counterparts24,25. Doses of 30 or 45 µg HA of
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whole inactivated vaccine virus or 45 µg split vaccine adminis-
tered twice barely induce haemagglutination inhibition (HI)
titers24,26,27.
Adjuvants can improve, steer, and broaden the immune
response and consequently improve the efficacy of vaccines28,29.
To overcome the poor immunogenicity of H7N9 vaccines,
adjuvants such as aluminum hydroxide, AS03 and MF59 have
resulted in a significant improvement of the immune response in
humans24,26,27,30. In ferrets, addition of adjuvants greatly improved
protection31,32 even against antigenically distinct HPAI H7N9
infection33. However, a major obstacle for application in pandemic
influenza vaccines in low-income countries is the potential lack of
access to proprietary adjuvants.
Aluminum hydroxide is a commercially available adjuvant but
only induces a modest pandemic influenza antigen-sparing
capacity compared with oil-in-water emulsions such as the
proprietary adjuvants AS03 (GlaxoSmithKline) and MF59 (Novar-
tis)24,27. We therefore selected the SWE adjuvant, which is free of
intellectual property rights. This adjuvant has been developed by
the Vaccine Formulation Laboratory for technology transfer in
order to empower developing countries vaccine manufacturers to
increase pandemic influenza vaccine capacity34,35. SWE is an oil-in-
water emulsion of similar composition to MF59, and has
previously been successfully used in preclinical studies with
various vaccine candidates against poliovirus36, Leishmania37,
RSV38, Malaria, Hepatitis B, Tuberculosis39, and rabies40 and is
awaiting clinical testing.
Here, we evaluate an H7N9 split vaccine formulated with or
without SWE adjuvant in the ferret model at different dose levels.
We show that addition of the adjuvant has a strong immunopo-
tentiating- and therefore dose-sparing effect and allows for the
induction of cross-reactive antibodies against H7 strains from
different lineages. Both vaccines protect against severe pneumo-
nia induced by intratracheal infection, whereas the adjuvanted
vaccine requires a lower dose of antigen to accomplish this.
Furthermore, cluster analysis indicates that ferrets vaccinated with
the non-adjuvanted vaccine may be more easily pushed towards
severe disease progression.
RESULTS
Antibody response
When ferrets were immunized with split vaccine without adjuvant,
low antibody levels were detected in all functional assays
irrespective of dose, which in general declined after day 13 (Fig.
1). In half of the animals, no HI-titer was detected and a second
vaccination 21 days later did not boost the HI-response. Booster
vaccination did increase NI- and VN-titers, and these were
detectable by day 37 in all split-vaccinated animals (P < 0.01 vs.
placebo).
Addition of the SWE adjuvant had a clear immune-potentiating
effect, as the titers of the functional antibodies were significantly
higher than in the placebo and split alone vaccine groups (Fig. 1).
The majority of the animals responded after a single administra-
tion (P < 0.05 vs placebo for VN- and NI-titers at day 13 and 20).
After booster, high titers in all animals in all assays were detected
(P < 0.01 vs placebo). The HI and VN responses at day 37 were
significantly higher than in the two split vaccine without adjuvant
groups. The NI-titers were significantly higher for the 15 µg
adjuvanted vaccine compared with the 45 µg split alone vaccine
at day 20 and 37. There was no measurable difference between
the groups immunized with different doses of the adjuvanted split
vaccine in either of the assays.
Cross-reactive antibody response
To investigate potential cross-protection against divergent
H7 strains, we assessed cross-reaction by HA-inhibition against
H7 strains from the Eurasian and North American lineages (Fig. 2),
including two Eurasian highly pathogenic H7N9 strains that
recently emerged and were selected as new H7N9 vaccine
candidates by the WHO41.
Homologous HI-titers generated by the split vaccine alone were
mostly absent, accordingly cross-reaction was not detected,
except for some responses against the H7N9-HongKong strain.
In contrast, the adjuvanted vaccines showed strong cross-reaction
against all tested strains with exception of the H7N8 strain. In
general, the average cross-reactive HI-titers were ~2–3 dilutions
lower than the titers against the homologous strain and ranged
between 40 and 160. Even the response against the H7N2 virus,
Fig. 1 Functional and neutralizing antibody responses. Haemagglutination inhibition, neuraminidase inhibition, and virus neutralization
antibody titers detected during the course of the study in serum of ferrets that received either the split vaccines alone (45 µg HA—blue circles,
15 µg HA—red triangles) or the SWE-adjuvanted split vaccines (15 µg HA—green open circles, 7.5 µg HA—purple diamonds). HI-Titers were
measured against four haemagglutinating units H7N9 (A/Anhui/1/2013) using a concentration of 1% horse erythrocytes. NI-titers were
determined using an H6N9 (RN19/13-human reassortant strain) dilution with a neuraminidase activity resulting in an ~OD 1 after 1 hour
incubation at 37 °C. Inhibition of neuraminidase was considered at an OD of less than three times standard deviation below the maximal OD.
VN-titers were measured against 100 TCID50 of H7N9 and 50% Virus neutralization was calculated according to Reed and Muench
70. Presented
are the individual titers and a line connecting the geometric means. *p < 0.05; **p < 0.01, by the WMW test. Horizontal dotted line: detection
limit. Vertical dotted lines indicate: a. 1st vaccination; b. blood collection; c. 2nd vaccination; d. challenge.
J.de Jonge et al.
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which is from a different lineage (North American) was within this
range. Cross-reactivity against the H7N8 strain of the North
American lineage was clearly lower than against the other strains
and showed more non-responders.
Clinical manifestations
When the placebo-vaccinated ferrets were challenged via the
intratracheal route 17 days after booster immunization, they
became inactive and developed ARDS 2–3 days post challenge (d.
p.c., supplementary Table 1). A strong fever peak developed
within 24 h (max. ΔT of ~3 °C) followed by a second peak 2 d.p.c.
(Fig. 3). The average temperature increase during the interval after
challenge was ~1.2 °C (supplementary Table 2). By 2 d.p.c., the
ferrets had lost ~5% weight and at termination (3 d.p.c.) weight
loss had increased to ~10% (Fig. 3, supplementary Table 2). Finally,
two animals died and one animal had to be killed prior to
scheduled termination.
None of the vaccinated animals had to be killed prior to
scheduled termination and except for one ferret, none showed
the typical clinical symptoms that accompany an intratracheal
H7N9 infection (supplementary Table 1). All vaccines, except for
the 45 µg split vaccine alone prevented weight loss in all animals
(Fig. 3, supplementary Table S). In the 45 µg split vaccine group
reduced weight loss was observed as the maximum weight loss
was less compared with the placebo group (supplementary Table
S). Only the adjuvanted vaccines and the 45 µg split vaccine alone
prevented the development of fever. With the 15 µg split vaccine
alone, fever was still observed: the maximum temperature
increase was significantly higher than in the other three vaccine
groups and the average temperature increase significantly higher
than in the 7.5 µg adjuvanted group (supplementary Table 2). One
ferret in the 45 µg unadjuvanted split vaccine group (ID #07)
developed severe disease similar to the placebo group with less
activity, heavy breathing and substantial weight loss; however
without the typical fever.
Virus replication in the respiratory tract
In placebo-vaccinated animals, high virus titers of up to ~5.5 logs
(TCID50) were detected in the throat two and three d.p.c. and in
the trachea (~5.5 logs) and lung (~6.5 logs) three d.p.c. (Fig. 4).
Vaccination with 45 and 15 µg split vaccine alone reduced virus
replication in the throat significantly at 3 d.p.c., but virus titers
were still detectable. Viable virus in trachea and lung could not be
detected, except in three ferrets (ID#07, #12, and #13) with high
virus titers. Vaccination with adjuvanted split vaccine reduced
virus replication compared to the split vaccine alone, as throat
swabs taken two and three d.p.c. contained significantly lower
virus titers. Moreover, virus could not be detected in the trachea
and lungs of ferrets immunized with adjuvanted split vaccine.
Lung pathology evaluation
Lungs of placebo-treated ferrets appeared opalescent, edematous,
and swollen, three d.p.c. with H7N9 virus. In four out of six ferrets,
>80% of the lung surface contained dark lesions (Fig. 5a, c) and
microscopically 40–100% of the lung parenchyma was affected
(Figs. 5b, d). The infection had less impact on two ferrets of which
only <50% of the lung surface was affected. Owing to edema
accumulation, lungs weighed 3–5 times more than lungs of
healthy ferrets and ferrets showed a higher relative lung weight
(RLW, Fig. 5e) which is an indicator for advanced pneumonia. The
ferret of which 25% of the lung was affected showed a clearly
increased RLW of 2.2, indicating initiation of severe pneumonia.
In animals vaccinated with H7N9 split vaccine, either with or
without adjuvant, lungs appeared normal with <10% of the
surface affected (Fig. 5a, c). Less than 10% of microscopically
examined lung parenchyma (Figs. 5b, d) was affected and the RLW
was at or close to baseline (Fig. 5e). However, ferret #07 (45 µg
split vaccine) had clearly affected lungs (40%) and a high RLW
(2.05) and one ferret (#17) from the 15 µg split adjuvanted vaccine
group had increased affected lung tissue (microscopically). These
effects were only visible macroscopically as a scattering of small
spots. There were no significant differences between the different
dosages or between the adjuvanted and non-adjuvanted
vaccines.
Histopathological evaluation of lung pathology
Figure 6 shows representative histopathological illustrations of
lungs from placebo and vaccinated ferrets and the scores for the
different parameters per compartment to illustrate the scoring
system. A full analysis for the individual ferrets is presented in
supplementary Fig. 1.
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Fig. 2 Cross-reactive antibody responses. Cross-reactive antibody responses were determined by haemagglutination inhibition a Groups
that did not show any cross-reaction were left out. Presented are the individual titers, geometric means, and SDs. Horizontal dotted line:
detection limit. Significant lower responses compared to the homologous strains are indicated by *(p < 0.05) and **(p < 0.01), by the WMW
test. split vaccines alone: 45 µg HA—blue circles, 15 µg HA—red triangles, or the SWE-adjuvanted split vaccines: 15 µg HA—green open circles,
7.5 µg HA—purple diamonds. A phylogenetic tree of the divergent strains tested for cross-reactivity is shown in b. H7 HA’s are divided in two
lineages, the Eurasian and North American lineage. The numbers indicate branch length.
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Intratracheal infection with H7N9-induced severe pathology in
five out of six animals of the placebo group, characterized by a
moderate to strong bronchopneumonia, which spreads into the
interstitium and alveoli (Fig. 6a). Bronchiolar lumens are regularly
obstructed by exudates, with necrosis of bronchiolar epithelium of
inflamed bronchiolar walls (a1). Furthermore, inflammation was
also substantial in interstitial septa and in the alveoli (a3). In
addition, there was substantial alveolar damage characterized by
influx of edema, fibrin and debris, inflammatory cells, and
sometimes hemorrhage into alveolar space (a2 and a3). A mild
or strong inflammation is observed in part of the blood
vessels (a2).
In most vaccinated animals (Fig. 6c) the infection pathology was
restricted to a minimal peribronchiolitis (c1), sometimes combined
with a minimal perivasculitis and inflammation of the interstitium
(c2). Inflammation in the alveoli was absent. Damage of the
epithelial cell lining in the bronchioli was minimal (c1), absent to
minimal in the interstitium (c1–3) and in most cases absent in the
alveoli (c1). Panel b represents intermediate examples of a few
animals that were either from the placebo group and showed
milder effects than the group mean or from the vaccinated ferrets
that showed more pronounced effects than the general trend (See
supplementary Fig. 1).
An end score of the overall infection pathology for the lung was
determined, taking into account the amount of tissue affected, the
degree of inflammation and the amount of damage (Fig. 7). The
end scores for placebo-vaccinated animals ranged from 3 to 5. In
general, vaccination reduced these scores to 1 in all the different
vaccine-treated groups. Ferret #07 from the 45 µg split group also
developed a full-blown lung pathology (score 5) and two ferrets
from the non-adjuvanted vaccine groups showed minimal
pathology (score 2). In addition, a ferret in the 15 µg split
Fig. 3 Weight loss and fever. Body weight prior to challenge was set at 100% and percentage weight loss was subtracted from baseline a.
Presented are the individual data and lines connecting the averages: placebo (black squares), split vaccines alone (45 µg HA—blue circles,
15 µg HA—red triangles) or SWE-adjuvanted split vaccines (15 µg HA—green open circles, 7.5 µg HA—purple diamonds). Body temperature
was recorded every 30min by transponders that were placed in the intraperitoneal cavity. To analyze fever development, the temperature
difference compared with baseline was calculated and the average ΔT per group was plotted. The colored dotted lines indicate the standard
deviation. The several sharp decreases in temperature are a result of sedation required for sampling and challenge. Color coding is the same
as for the body weight graph. b.1 placebo; b.2 45 µg split; b.3 15 µg split; b.4 15 µg split-SWE; b5 7.5 µg split-SWE. Vertical dotted lines indicate:
a. challenge; b and c. swab collection; d. termination. WMW test: **p < 0.01.
J.de Jonge et al.
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adjuvanted vaccine group showed a moderate pathology (score
3). The latter was not reflected in the clinical symptoms, virus
replication and macroscopic lung pathology of this animal.
Between the vaccine groups there were no significant differences
with regard to lung pathology.
Correlation between antibody response and efficacy parameters
To be able to link vaccine efficacy to immunological parameters,
we studied the correlation between functional antibody responses
and vaccine efficacy parameters. We found strong associations
between these parameters using the independent test, most
associations had a p value < 0.0005 (Supplementary Table 3). Next,
representative read-outs for virus replication, clinical disease and
pathology were selected and curves were fitted to the data to
reveal the nature and accuracy of the correlations (Fig. 8a).
The curves best describe the correlation between NI- and VN-
titers and lung viral titers (R2 > 0.90; Fig. 8a). There is also a good
correlation between NI- and VN-titers and RLW (R2 > 0.67), but less
between antibody titers and fever (R2 ≤ 0.60). Strikingly, the
correlation between the HI-titers and efficacy parameters was
poor, as R2 was much lower than for the NI-and VN-titers. This
reflects the, in general, higher p values for associations between
the HI-titer and efficacy parameters in the independent test
(supplementary Table 3).
Based on the fitted curves, the level and nature of protection
provided by antibody titers was estimated. When vaccines induce
VN-titers of ≥400 and NI-titers of ≥40, virus replication in the lung
remains below detection level. To protect against lung pathology,
lower antibody levels are required: ≥160 VN-titers and ≥20 NI-
titers, determined at 1% RLW (baseline). The curves cannot be
used to determine protective levels of HI-titers owing to the great
uncertainty within the lower range of the observations. However,
at HI-titers of ≥40, no virus replication and lung pathology are
observed. Severe fever is already reduced at titers below above
mentioned levels. On the other hand, fever cannot be totally
prevented and, despite vaccination, a mild fever is still likely
to occur.
The poorer sensitivity of the HI-assay is further illustrated in Fig.
8b, which shows that VN- and NI-titers are already detected when
no HI-response is observed. Contrary, VN- and NI-titers show an
initial linear relation, implying equal sensitivity. The sigmoid Emax
model (highest R2 of the four tested models) fitted to the data
underline these observations.
Cluster analysis
To analyze and comprehend large data sets, algorithms have been
developed to visualize associations between objects. Cluster
analysis is a treatment-blind descriptive algorithm that identifies
groups (clusters) of similar objects within a population. We used
this analysis to visualize general patterns in the ferret study
population with respect to vaccination and how individual animals
relate to these patterns.
As a representative for the overall immune potency of the
vaccines, including the effect of priming and boosting, the area
under curve (AUC) of the log-transformed antibody titers in time
was calculated for each functional antibody assays and used for
cluster analysis of the antibody response. This clusters ferrets
based on their similarity in immune responses. To visualize the
overall vaccine efficacy, a second cluster analysis was performed
on selected efficacy read-outs, including all virus replication,
weight, fever and pathology (excluding ordinal data) parameters.
Both data sets passed the Hopkins test (H value <0.5), meaning
they were clusterable (H value: 0.29 and 0.25 for antibody
response and efficacy, respectively).
As part of cluster analysis, distances between all combinations
of two ferrets were calculated with the Euclidean method for both
data sets. These are represented in dissimilarity matrices that
show the distance between two objects (supplementary Fig. 2A).
The distance calculation was used as input for the partitioning
around medoids (PAM) clustering algorithm to identify clusters.
Next, we determined the number of clusters by performing the
analysis using 2–5 clusters followed by a cluster validation test
using a silhouette plot (supplementary Fig. 2B). This approach
showed that, either two or four clusters for both data sets were
optimal. In our analysis, we proceeded with four clusters as this
revealed more detail.
For the antibody response, Fig. 9a shows the four clusters
identified in the ferret study population that range from no or low
antibody responses (blue#1 and yellow#2 cluster) to medium
responses (gray#3 cluster) to high responses (red#4 cluster). The
adjuvant effect is clearly visible as cluster 4 only contains the
adjuvanted vaccine and only three animals of the adjuvanted
groups are located in cluster 3. The non-adjuvanted vaccinated
ferrets respond much more heterogeneous as these are located in
three clusters that represent medium to no antibody response.
The latter includes all the placebo animals.
The four clusters that are identified within the efficacy data set
decrease in severity from left to right (Fig. 9b). They can roughly
be divided into two categories that either include animals with
Fig. 4 Virus replication in the respiratory tract. Virus titers in the throat, 2 and 3 days post challenge (d.p.c.) and in the trachea and lung 3 d.
p.c. in ferrets vaccinated with placebo (black squares), split vaccines alone (45 µg HA—blue circles, 15 µg HA—red triangles) or SWE-
adjuvanted split vaccines (15 µg HA—green open circles, 7.5 µg HA—purple diamonds). The virus titers in the transport buffer of the swabs or
homogenized tissue samples were determined by end-point titration on MDCK cells using a fivefold serial dilution. Presented are the
individual 10 log-transformed titers, their averages (bar) and SD (error bar). Dotted horizontal lines indicate limit of detection. One animal of
the placebo group was excluded as this animal died ~1 day before section. Another animal of the placebo group that died prior to section
was still included as the time of death was only a few hours before section. WMW test: *p < 0.05; **p < 0.01.
J.de Jonge et al.
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severe disease (blue#1 and yellow#2 cluster) or those that include
animals that are protected (gray#3 and red#4 cluster). The yellow
cluster (#2) contains less severely affected animals compared with
the blue cluster (#1). Subjects in the gray cluster (#3) show more
mild disease/pathology or virus replication than ferrets in the red
cluster (#4), who are almost completely protected.
Addition of the SWE adjuvant evidently improves the efficacy of
the vaccine, as all animals except one that received this vaccine
are located in cluster 4 (Fig. 9b). Again, the non-adjuvanted
vaccine leads to a heterogeneous distribution over the clusters as
some ferrets (n= 5) are in cluster#4, whereas others (n= 4) are in
cluster#3 and two ferrets are in cluster #1 or #2. A dose effect
could not be confirmed, as both non-adjuvanted groups are
located in the different clusters. Likewise, a dose effect for the
adjuvanted vaccine could not be established, as ferrets locate to
just one cluster.
Animals that belong to the highest antibody response cluster
(#4 in Fig. 9a), also belong to the cluster that represent near
complete protection (cluster#4, Fig. 9b). Likewise, ferrets in cluster
1 (Fig. 9a) localize to clusters 1 or 2 in Fig. 9b, representing severe
disease, although there are exceptions, as animal #12 localizes to
the gray cluster (#3, Fig. 9b) in the efficacy analysis. The
connection between the clusters of the two analysis shows there
is a relation between the antibody titer and protection, but that a
low antibody response not necessarily predicts disease. These
observations are consistent with the correlation analysis
performed above.
Thus, cluster analysis provides a representative overview of all
the results and reveals individual ferrets that respond differently
Fig. 5 Macroscopic and microscopic illustrations and analysis of lung pathology. Macroscopic illustrations of the lungs a and microscopic
illustrations of hematoxylin and eosin HE-stained lung sections b to exemplify the scoring of the percentage affected lung tissue (shown in
the table). a and b, numbers 1–4 are typical for the placebo group and numbers 5 and 6 for the vaccine groups, excluding the outliers. Means
and SDs of macroscopically c and microscopically d estimated percentages of affected tissue. The relative lung weight (RLW) was calculated as
the ratio of the lung weight at termination to body weight at the day of challenge e. Corresponding RLW’s to the illustrations in a, are shown
in the table. Bar in a: 3 cm and bar in b: 0.5 cm. WMW test: *p < 0.05; **p < 0.01 compared with the placebo group.
J.de Jonge et al.
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than the group trend. The analyses show that addition of the
adjuvant results in a higher immune response and a far more
robust efficacy and that a low dose (7.5 µg HA) is sufficient. When
immunizing with the split alone vaccine, the animals may much
easier tip towards severe disease progression, as many of the
animals are in a cluster closer to the placebo group and some
ferrets already localize with the placebo group clusters.
DISCUSSION
We here examined an H7N9 split vaccine, either with or without
the SWE oil-in-water adjuvant, at different dose levels and found
that the adjuvant clearly enhanced haemagglutinin- and neur-
aminidase inhibition and virus-neutralizing antibody responses.
The adjuvanted vaccine protected against severe pneumonia and
virus replication and clinical signs, such as weight loss and fever
were almost absent. Despite an impaired induction of a humoral
response, the non-adjuvanted split vaccine protected in almost all
cases from severe pneumonia, but virus replication, fever, and
weight loss were less successfully prevented. Using cluster
analysis, we visualized that the addition of the adjuvant results
in robust protection and that a low dose was sufficient, whereas
the protection induced by the split-alone vaccine is heteroge-
neous, indicating that in these animals the balance may be more
easily tipped toward severe disease progression.
Potentially pandemic H7N9 influenza virus is low immunogenic
in humans42 and consequently even high doses (30–45 µg HA) of
whole inactivated virus vaccines or split vaccines induce incon-
sistent and low HI-titers in humans24,26,27 and in ferrets31,43. The
latter underpins that the ferret model reflects the human situation
and adds to the ability to extrapolate ferret antibody results to the
clinic. In our study, these observations were confirmed as split
Fig. 6 Detailed histopathological analysis of the lung. a–c Representative hematoxylin and eosin (HE)-stained lung sections to illustrate the
scoring system of pathology parameters. Scores of the pathology parameters that go along with the images (a.1-c3) are indicated in the table.
All individual scores are presented in supplementary Fig. 1. Bronchioli and blood vessels are marked in blue and green, respectively.
Enlargements: ×10 objective, bar represents 100 µm. a images a.1–3 are representative sections for the placebo groups and illustrate
necrotizing denudation of bronchioli with luminal plugs of inflammatory exudate (a.1,*), accompanied by a large peribronchiolar rim of
lymphocytes and some polymorphonuclear (PMN) cells (a.1,+). Inflammation is spread into the interstitium (a.1, ↖) and alveolar space (a.3,
↖). Hyperemia is strongly present and alveolar space is filled with edema, fibrin, and debris and PMN are regularly present (a.2 and A.3, ○).
Inflamed small arteries with perivascular inflammation are also observed (a.2, +). b images b.1–3 are typical for a few placebo- and split-
vaccinated animals that were either less or more affected than the general trend, respectively. Bronchioli with moderate peribronchial
inflammation (b1, +) and hyperplasia of epithelium (b.1,↖). Alveolar septa with mild or slight (b2,↖) inflammation and hyperemia and alveoli
filled with erythrocytes (b3, ○). c images c.1–3 are representative for the split-vaccinated ferrets. Observable are a bronchiolus with minimal
peribronchiolar inflammation and hyperplasia of epithelium (c.1, +), alveolar septa with minimal inflammation and hyperemia (c.1, c2↖) and
minimal inflammation of the alveoli (c.2). The small vene minimally inflamed (c.2, +). c3 shows a normal histology of the lung parenchyma.
Presence of normal bronchiolar epithelia and a blood vessel, regular alveoli with thin septa and absence of enhanced cellularity.
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vaccine alone (15 and 45 µg HA) induced an antibody response
only in half of the animals, which declined rapidly and boosting
did not increase HI or NI titers. Addition of adjuvants can
overcome the low immunogenicity of H7N9 as several preclinical
and clinical studies have shown24,26,27,31. We here show that the
SWE adjuvant effectively boosts functional antibody responses
(VN-, NI-, and HI-titers).
The usability of the vaccines tested during GAP stands or falls
with their cross-reactive potency, as H7N9 diverges2,6. We
therefore investigated cross-reactive HI-titers against strains from
the Eurasian as well as the North American lineage and recently
emerged HPAI H7N9 strains. Only the SWE-adjuvanted vaccines
induced cross-reactive HI-antibodies of significant titers against
Eurasian strains, including the newly emerged HPAI strains and
against an H7 strain of the North American lineage. Previously
Hatta et al.33 showed that a LPAI H7N9 whole-inactivated virus
vaccine cross-reacted and provided protection against HPAI H7N9
challenge in ferrets. Also others have shown that H7 vaccines
cross-react and protect against drifted H7 influenza strains in
mice44. Therefore, the cross-reactive HI-titers found in this study
are an indication that the SWE-adjuvanted split vaccines may
cross-protect against divergent H7 strains.
Ferrets are readily infected by influenza strains that infect
humans and express comparable clinical manifestations45–47,
partly owing to the similar lung physiology and sialic acid
receptor distribution in the respiratory tract. Often the intranasal
infection model is used for investigating vaccine effective-
ness31,32,43,48,49, however for H7N9, this route of inoculation
results in fairly mild disease50–53, which does not reflect the
disease observed in the severe human cases1,3,4,54–56. Also, lung
viral titers could not be reproducibly induced through this
route31,52. Results from these studies are therefore difficult to
extrapolate to humans in terms of protection against disease. They
should be viewed in the light of prevention of virus replication in
the upper respiratory tract, which is an obvious important
parameter in a pandemic situation as this would limit
transmission. Despite the unnatural route of infection, intratra-
cheal inoculation of ferrets with H7N9 induces severe bronch-
opneumonia resulting in ARDS53,57, in line with clinical findings in
severe cases1,3,4,54–56. Vaccine studies in this model53,58 likely have
a better predictive value for effectiveness against disease in
humans. We here show, by detailed analysis of the clinical
manifestations and in depth pathological analysis, that the
adjuvanted split vaccine and, to a lesser extent, the unadjuvanted
split vaccine protect against severe pneumonia and ARDS induced
by intratracheal infection. The limitation of the i.t. model is that
there is no consistent virus replication in the upper respiratory
tract, and therefore well-founded conclusions with respect to
shedding cannot be made. Yet, it may be assumed based on
strongly limited virus replication in the throat and lung, that the
split vaccines would limit virus shedding too. Therefore, the route
of infection should be carefully considered with regard to which
protection parameter is investigated to determine vaccine
efficacy.
As the split vaccines induced a range of functional antibody
titers, the correlation of these responses with protection against
infection could be studied. There was a strong association
between functional antibody responses and vaccine efficacy
parameters. Higher values of R2 are observed in the relations
involving VN- and NI-titers than in those involving HI-titers. Curve
fitting showed that protection increased sigmoidally with increas-
ing NI- and VN-titers, whereas for HI-titers only when above a
threshold there was a clearer correlation with protection. It was
calculated that VN-titers of ≥400 and ≥160 and NI-titers of ≥40
and ≥20 protected against virus replication in the lung and lung
pathology, respectively. However, these are indications as for
accurate estimates more data are required. Animals were
protected from severe fever at low functional antibody titers,
but mild fever could not be completely prevented, even with high
functional antibody titers. In addition, correlation analysis showed
that the NI-, and VN-data are more predictive in the lower range
than the HI-data and when NI-, and VN-titers could not be
detected, the animals were not protected. In contrast, when HI-
titers were absent, some animals were still fully protected.
Therefore, the NI and VN antibody titers are each independent
predictors for vaccine efficacy and predictions based on the HI-
assay may lead to an underestimate of protection. This has been
observed in other studies in ferrets43 but also in humans59.
NI-antibody titers have been shown as an important correlate of
protection59–63. Recently, the waning vaccine effectiveness for
H1N1 has been attributed to immune escape of NA, whereas HA
did not show significant antigenic drift64. In two human challenge
studies NI was the only independent predictor for clinical
outcome59,62. The results of the current study are in line with
the findings in the clinic and stress that Neuraminidase should be
included in sufficient amounts in the vaccine to assure a better
and broader efficacy.
We used cluster analysis, which is an unbiased algorithm that
identifies groups of subjects in a population, called clusters, based
on similarity, to analyze the disparate data set in this study. We
analyzed the antibody response results and the efficacy results
separately. The outcome showed that ferrets immunized with
SWE-adjuvanted vaccine localized to the cluster with the highest
antibody response and to the cluster containing ferrets that were
best protected against challenge. The efficacy was very robust as
only one animal fell out of the latter cluster. Vaccine dose
differences had no effect on clustering. For the non-adjuvanted
vaccinated animals, clustering was highly heterogeneous both for
the antibody responses and efficacy measurements. Animals
located in several clusters, including those that contained placebo
animals. The added value of cluster analysis is that it provides a
clearer picture of the performance of the different vaccine
formulations than when considering assays individually. It also
helps in interpreting possible outliers or a high variation in assay
Fig. 7 Pathology ‘end score’. The end score is an overall pathology
score, which is determined based on the amount of tissue affected,
the degree of inflammation and the amount of damage in the left
caudal and cranial lung lobe. The scores range from 0 (no
aberrations) to 5 (severely affected). Statistical analysis was
performed using an adapted version of the Mann–Whitney test for
ordinal data with a small sample size: *p < 0.05; **p < 0.01 compared
with the placebo group.
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ab
Fig. 8 Correlation analysis between functional antibody responses and vaccine efficacy parameters. a Correlation between VN-, NI-, and
HI-titer and virus replication in the lung, fever, and pathology visualized by interpolation (dashed line) using the sigmoid emax model for virus
titers and RLW and the Emax model for fever. Antibody titers were determined at the day of challenge (day 37). Vaccine treatment is indicated
by shape and color. R2 indicates the goodness of the fit. Lung viral titers were selected because the lung is the organ of direct vital importance
and should be protected. Fever and relative lung weight (lung pathology) as clinical and pathological parameters were preferred, because
they contained more measurements and/or are not based on a subjective scoring system. b Correlation between the different antibody titers
at day of challenge visualized by interpolation using the sigmoid Emax model.
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outcome and shows that these may be indicative of a fragile
protection balance that can easily be pushed towards severe
disease in non-adjuvanted split-vaccinated ferrets.
Vaccine production capacity is limited and not sufficient in the
event of a pandemic. A substantial dose-sparing capacity of an
adjuvant is therefore an important requirement. The cluster
analyses show that the SWE-adjuvanted low dose (7.5 µg) vaccine
performs better than the high dose (45 µg) split alone vaccine
with respect to the antibody response and vaccine efficacy. Thus,
addition of the SWE adjuvant to the split vaccine increases the
amount of vaccines that can be produced by at least a factor six,
which is crucial for vaccine availably in a pandemic situation.
Other vaccines against H7N9 with a previously proven seasonal
track-record have been developed. These have shown to be
effective in preclinical models and immunogenic in the clinic and
include live attenuated influenza vaccines53,65, and split and
whole-inactivated virus vaccines24,26,27,30. Each vaccine will have
its pros and cons, but in the face of a pandemic all these vaccines
will be required, as the major limitation will be the production
capacity66. Here, we show that adjuvants can play an important
role, not only in the efficacy of the vaccine, but more importantly
in the dose-reduction effect and cross-reactive response induc-
tion. Until universal influenza vaccines becomes available with
lasting efficacy, developing and testing “classical” vaccines up to
clinical phase I/II studies and including adjuvants to broaden the
immune response remains the road to travel and the current study
contributes to this strategy.
METHODS
Ethical statement
The animal experiments were ethically approved by the Committee on
Animal Experimentation of the Antonie van Leeuwenhoek terrain (DEC-Alt,
Bilthoven, the Netherlands). Animal handling was carried out in
compliance with relevant Dutch national ethical legislation, including the
1997 Dutch Act on Animal Experimentation. Animals were examined for
general health on a daily basis. After challenge, ferrets were scored twice
daily for activity, impaired breathing, and survival. The following scoring
system was used for activity: 0=active; 1=active when stimulated;
2=inactive and 3=lethargic; and for Respiratory distress: 0=normal
breathing; 1=fast breathing and 2=heavy and stomach breathing. If
animals showed severe disease according to the defined end points
(lethargic or heavy breathing and inactive or more than 20% weight loss)
prior to scheduled termination, they were killed by cardiac bleeding under
anesthesia with ketamine (5 mg/kg) and medetomidine (0.1 mg/kg).
Viruses
H7N9 A/Anhui/1/2013 wild-type influenza virus as well as H7N9 A/
Guangdong/17SF003/2016 reassortant (NIBRG-375) and H7N2 A/NewYork/
107/2003 reassortant (NIBRG-109), both prepared by reverse genetics, were
obtained from the NIBSC under the conditions of the Pandemic Influenza
Preparedness (PIP) framework. A/Netherlands/33/03 (H7N7) and A/mallard/
Netherlands/12/00 (H7N3) were obtained from the repository of the Centre
for Infectious Disease Control of the RIVM (Bilthoven, the Netherlands). The
H7N9 vaccine strain (A/Shangai/2/2013(H7N9)-PR8-IDCDC-RG32A.3) and
the wild-type H7N9 A/HongKong/125/2017 were provided by the CDC
(Center of Disease Control, USA) and H7N8 A/Turkey/Indiana/16-001403/
2016 was obtained from the Animal and Plant Health Inspection Service
from the USDA. RN9/13-human A(H6N9) reassortant was obtained from
the Institute of Experimental Medicine (St. Petersburg, Russia)53.
Vaccine
The master seed bank and the working seed bank of the H7N9 vaccine
virus were produced under good manufacturing practices (GMP) condi-
tions. For the production of the split H7N9 vaccine antigen under GMP
conditions, the diluted H7N9 vaccine strain from the working seed bank
was inoculated into embryonated chicken eggs (10–11 days old) and
incubated at 33–35 °C for 60 h. After incubation, the eggs were chilled at
2–8 °C and the allantoic fluid was manually harvested and clarified by
centrifugation. The virions were purified by two consecutive ultracen-
trifugation steps of sucrose gradient, collected, diluted with phosphate
buffer and fragmented by Triton X-100 treatment (0.5% final concentra-
tion). The split H7N9 was further clarified by centrifugation and diafiltration
(cutoff 50 kDa, using phosphate buffer, 10 times the initial volume). After
appropriate dilution, formaldehyde was added to 0.01% final concentra-
tion for inactivation. The H7N9 antigen was filtered in 0.22 µm filter and
Fig. 9 Cluster analysis of the antibody response and efficacy measurements. Cluster analysis using the partitioning around medoids (PAM)
algorithm as a descriptive statistical approach to visualizer overall trends in the ferret study population. Subjects are plotted using a principal
component analysis and clusters determined by PAM are indicated by ellipses. a Clustering of the antibody response based on the area under
curve (AUC) of the log-transformed antibody titers from D0 until D37. b Clustering of the efficacy parameters based on assays with numerical
data output including virus replication, weight, fever, and pathology parameters (excluding ordinal data). Labels indicate vaccine dose with or
without adjuvant and animal number. Pl placebo.
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considered concentrated H7N9 vaccine antigen bulk. Quality control of
H7N9 vaccine antigen was performed according to the WHO guidelines67
and the H7 haemagglutinin content of the bulk was determined by single
radial immunodiffusion assay67 using reference anti-H7 hemagglutinin
antibodies and H7 hemagglutinin antigen from the NIBSC (UK). The
vaccines were prepared freshly from the bulk at the day of vaccination by
diluting with phosphate-buffered saline (PBS) to the desired concentration.
The adjuvanted vaccines were prepared by admixing the SWE adjuvant in
a 1:1 volume ratio on site. All vaccines were for prepared in a volume of
0.5 mL.
Adjuvant
SWE is a squalene-in-water emulsion adjuvant comprising a metabolizable
oil (squalene 3.9%, w/v), sorbitan trioleate (0.47%, w/v), and polyoxyethy-
lene (80) sorbitan monooleate (0.47%, w/v) dispersed in 10mM citrate
buffer at pH 6.5. Manufacturing of SWE was performed by adding an
aqueous phase containing polyoxyethylene sorbitan monooleate in citrate
buffer at pH 6.5 to the oil phase, containing squalene and sorbitan
trioleate35. The mixture was homogenized with a high-shear mixer
(Silverson L5M-A) at 8000 rpm for 2min and immediately microfluidized
(Microfluidics M-110EH) with five passes at 20,000 psi while cooling at
10 °C. The final emulsion was sterilized by filtration and characterized by
assessing visual appearance, measuring pH, determining particle size by
dynamic light scattering, squalene concentration by reversed-phase high-
pressure liquid chromatography, endotoxin content, sterility, zeta poten-
tial, osmolarity, squalene oxidation, and presence of large particles.
Ferrets and handling
Female ferrets (Mustela putorius furo), aged 6–12 months were confirmed
to be negative for previous infection with circulating influenza virus and
Aleutian disease. A temperature transponder (DST micro T, Star-Oddi) was
implanted intra-abdominally 14 days prior to commencement of the
experiment, which recorded the temperature every 30min. For this
purpose, sevoflurane was used as an anesthetic and buprenorphine
(0.2 mL subcutaneously) as a post-operative analgesic. Blood sampling,
immunizations, swabs, and challenge were performed under anesthesia by
ketamine (5 mg/kg) and medetomidine hydrochloride (0.1 mg/kg) and the
anesthesia was antagonized with atipamezole (0.25 mg/kg). After intra-
tracheal challenge, ferrets were antagonized after 30min to avoid sneezing
and coughing reflexes. All animals had ad libitum access to pelleted
standard ferret food and tap water.
Immunization and challenge of ferrets
Groups were intended to include six ferrets each. However, two ferrets had
to be terminated owing to a tumor development and a bacterial infection
prior to start of the study and during the vaccination period, respectively.
Ferrets were intramuscularly vaccinated (0.5 mL) twice at day 0 and 21 with
a placebo, an H7N9 split vaccine at a dose of 15 or 45 μg HA or a SWE-
adjuvanted H7N9 split vaccine at a dose of 7.5 or 15 μg HA. The 45 μg split
vaccine group contained five ferrets from the start of the study and the
7.5 μg adjuvanted group contained five ferrets from Day 31 and onward.
Serum samples were collected at regular time intervals (day −1, 13, 20, 37,
and 41) and stored at −20 °C for serological analysis. Thirty-eight days after
start of the study, the animals were challenged intratracheally with WT
influenza A/Anhui/1/2013 (H7N9, 107 TCID50 in 3mL). This dose was
obtained from a previously performed dose-titration infection experiment
and resulted in the most consistent induction of lung pathology and
disease. Prior to challenge and 2 and 3 days after challenge, throat swabs
were taken and ferrets were weighed. Swabs were vortexed in 2 mL
transport medium (15% sucrose, 2.5 μg/mL Fungizone, 100 U/mL Penicillin,
100 μg/mL Streptomycin, 250 μg/mL Gentamicin in PBS) and were stored
at <−70 °C until further virological analysis. Ferrets were scored twice daily
for the clinical parameters activity and impaired breathing according to the
following scoring system: 0=active; 1=active when stimulated; 2=inactive
and 3=lethargic and 0=normal breathing; 1=fast breathing and 2=heavy
and stomach breathing, respectively.
At day 41, animals were killed by cardiac bleeding. During section, the
trachea was clamped off after inhalation and the inflated lungs were
isolated, weighed, examined for gross pathology and photographed. The
middle section of the trachea (~1 cm) and a section of the three right lung
lobes and the accessory lobe along the proximodistal axis (~1 cm by 3mm)
were isolated and stored at −70 °C for virological analysis. The left cranial
and caudal lung lobes were fixed in 10% buffered formalin for
histopathological analysis.
Serological analysis
HAI titers in ferret sera were determined according to standard methods
with a modification for H7N9 antibody responses68. Ferret sera were
inactivated (30 min at 56 °C), treated with receptor destroying enzyme
(RDE, Sigma-Aldrich), twofold serially diluted and tested in duplicate
against four haemagglutinating units of the respective viruses using 1%
horse red blood cells. The HI-titer was calculated by taking the average of
the duplicate.
Virus neutralizing (VN) titers were determined as described elsewhere69.
Sera were inactivated (30 min at 56 °C) and twofold serially diluted in virus
growth medium (MEM medium (Gibco, 31095), 40 µg/ml gentamycin
(Sigma), 0.01 M Tricin (Sigma) and 2 µg/ml TPCK-treated trypsin (Sigma))
using a starting dilution of 1:8. An equal volume of virus at a concentration
of 100 TCID50 was added and the mixture was incubated for 2 h at 37 °C. In
addition, a back titration of the virus stock used for incubation with the
serum dilutions was prepared by ½log10 serial dilutions. Following, the
virus-serum mixture and the back-titration samples were transferred to 96-
well plates containing confluent Madin-Darby canine kidney (MDCK) cells
and incubated for another 2 h at 37 °C, 5% CO2 after which the medium
was refreshed. Plates were incubated until a back-titration plate reached
cytopathic effects (CPE) at a titer of 100 TCID50 (4–5 days). The 50% virus
neutralization titers per mL serum was calculated by the Reed and Muench
method70. The neuraminidase inhibition (NI) assay was performed as
described by Lambre et al.71. For this purpose, 96-well plates (Immulon
2HB, Thermo Scientific) were coated overnight with 100 μl of 50 μg/ml
fetuin (Sigma-Aldrich, USA). Twofold serial dilutions of serum were
prepared in duplicates and incubated with RN9/13-human A(H6N9) at a
standardized neuraminidase activity (OD450= 1 after 1 h incubation at
37 °C). Following, 100 μl of the virus/serum dilutions were transferred to
the fetuin-coated wells. After 4 h incubation at 37 °C, the plates were
washed with PBS/Tween20 (0.5%) and supplemented with 100 μl of
peroxidase-labeled peanut lectin (2.5 μg/ml; Sigma-Aldrich, USA), incu-
bated for 1 h at 37 °C and washed again. Peroxidase substrate (TMB, 100 μl)
was added and the reaction was stopped after 10min with 100 μl of 2 M
sulfuric acid. The OD450 was read using the EL808, Bio-Tek Instruments Inc,
USA and the NI-titer was determined from the last dilution with an
OD450 ≤ (OD450 of the virus control− 3× SD).
Animal temperature and weight
Temperature data were retrieved from the implanted temperature loggers
with the Mercury (v4.91) software and consisted of measurements taken
every 30min. Body weight data consisted of a single measurement
maximally once per day at the indicated days. Body weight and
temperature baselines were calculated as the average body weight and
temperature over a period of 2 (body weight) and 7 days (temperature)
prior to infection or challenge. The change in temperature and body
weight (ΔT and Δweight) was calculated by subtracting the baseline from
the measurement after infection or challenge. The sum of all these
measurement divided by the number of measurements is the average
change in body weight or temperature. The maximum change in body
weight or temperature was the maximum change compared to baseline
recorded during any of the measurement after infection or challenge.
Virus quantification
Lung and trachea samples were homogenized using FastPrep (MP
Biomedicals) homogenizer and clarified by low speed centrifugation and
transport medium from the swabs was used directly. Virus titers were
determined by end-point titration on MDCK cells according to a protocol
published by the WHO69. For this purpose, MDCK cells were seeded in 96-
well plates at a density of 1–5 × 104 cells/well and incubated at 37 °C until
90–100% confluence. Viral samples were five-fold serially diluted in 100 μL
virus growth medium (MEM medium (Gibco, 31095), 40 µg/ml gentamycin
(Sigma), 0.01 M Tricin (Sigma) and 2 µg/ml TPCK treated trypsin (Sigma)).
The cells were inoculated in sextuplets with the titrated viral samples and
after six days of incubation at 37 °C, wells were scored for CPE. The TCID50
titer was determined by the Reed and Muench70.
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PATHOLOGY
After fixation, the left cranial and caudal lung lobes were
embedded in paraffin. Sections were cut at a thickness of 5 µm
and stained with haematoxylin and eosin. Slides were examined
microscopically with an objective of ×4 or ×10. For evaluation of
the infection pathology, two pathology categories were defined
that included parameters indicating damage of the epithelial
lining and inflammation related parameters. These were analyzed
for the different compartments of the lung: bronchi(oli), inter-
stitium, alveoli, and blood vessels. Damage related parameters
included hypertrophy, hyperplasia, flattened or pseudo squamous
epithelia, necrosis and denudation of bronchi(oli) epithelium,
hyperemia of septa and alveolar emphysema and hemorrhages.
Inflammation related parameters included (peri)bronchi(oli)tis,
interstitial infiltrate, alveolitis and (peri)vasculitis characterized by
polymorphonuclear (PMN) cells, macrophages and lymphocytic
infiltrate. These categories were semi-quantitatively scored on a
scale of 0 (no aberrations) to 5 (severe damage) resulting in two
scores: one for damage, and one for inflammation, each for the
bronchi(oli), interstitium, alveoli, and blood vessels. At least 6
microscopic fields were scored for each lobe. The affected
percentage lung surface was estimated with an objective of ×2.
Finally, an end score was determined by taking into account the
severity and percentage of tissue affected by the various
parameters. Microscopic slides were randomized and scored
blindly. Images were processed in Adobe Photoshop CC
(v19.1.9) and only brightness and contrast was applied to the
whole image.
Phylogenetic tree
The phylogenetic tree was generated by the PhyML tool72
provided by the Influenza Research Database73.
Statistical analysis
All statistical analyses were performed in R (v3.6.0)74. Virus titers
and antibody titers were transformed by the logarithm to base 10
and the detection of differences between groups with respect to
these parameters was carried out with the one-tailed
Wilcoxon–Mann–Whitney (WMW) test provided in the coin
package (v1.2.1)75. Differences with respect to the pathology
scores were tested by an adapted version of the WMW test based
on mid p values, which were validated for ordinal data with small
sample sizes. Pairwise associations between various functional
antibody responses and parameters of vaccine efficacy were
tested by means of the permutation version of the ‘independence
test’ implemented in the coin package75. For the correlation
analysis, multiple testing corrections were carried out with the
Benjamini–Hochberg method76 at a nominal false discovery rate
of 5%. Curve fitting was performed using the DoseFinding
package (v0.9.16)77. The logistic, sigmoid Emax, Emax, and linear
models were tested and out of these the model with highest R2
was selected for fitting. Cluster tendency determination using the
Hopkin's test, distance matrix computation by the Euclidian
method and visualization was performed with the factoextra
package (v1.0.5)78. Cluster analysis was performed using PAM
included in the cluster package (v2.0.8)79 and cluster and
silhouette plots were created using the factoextra package
(v1.0.5)78.
Reporting summary
Further information on experimental design is available in the
Nature Research Reporting Summary linked to this article.
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